• Lupuzor

    Aiming to deliver a safe treatment for Lupus sufferers

    Read more

  • Innovative drug

    For the benefit of patients worldwide

    Read more

  • AIM listed

    Headquarters in London and research centres in France and Switzerland

    Read more

Recent announcements

Pharmaceutical drug development

Focused on making patient lives better

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

We continue to work with our long term partner Centre National de la Recherche Scientifique (CNRS), Europe’s largest fundamental research institution and ImmuPharma’s long standing collaboration partner.

AIM listed

Developing innovative drugs

ImmuPharma PLC is a pharmaceutical company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is focused on three therapeutic disease areas – Auto-immune (P140) | Oncology/Ophthalmology | Metabolism/Diabetes. Lupuzor™ is the Company’s most advanced drug candidate and is a treatment for Lupus, a life threatening auto immune-disease. Lupuzor™ received ‘Gold Standard’ approval from the US FDA for its Phase III trial with a Special Protocol Assessment and “Fast Track” designation. The Phase III trial has now been completed. ImmuPharma is led by a commercially focused Board and management team with extensive experience. Click here for the current corporate update in September 2018.

RNS announcements

Share Price

Market Cap

ImmuPharma transforms care for people worldwide

Developing innovative drugs for serious medical conditions

Lead program for the potential breakthrough compound for Lupus, the life threatening auto-immune disease

ImmuPharma has completed dosing Lupus patients in the USA, Europe and Mauritius in a pivotal Phase III clinical trial of Lupuzor™ with top line results announced.

Auto-immune diseases

Lupuzor™, is also known by its chemical name ‘Forigerimod’ or P140. ImmuPharma has the potential of expanding the P140 peptide platform into other auto immune conditions such as: Rheumatoid Arthritis, Crohn’s Disease, and Asthma. Very few AIM-listed drug development companies have late-stage clinical assets of similar calibre.

Oncology & Ophthalmology

ImmuPharma’s second most advanced pipeline program, IPP-204106, is a potential treatment for various cancers and acts by modulating angiogenesis (formation of new blood vessels) and proliferation (rapid reproduction). We are also investigating its use in age-related macular degeneration, diabetic retinopathy and other ophthalmological indications.

Metabolism and diabetes

ImmuPharma’s subsidiary ‘Ureka’ has initiated the development of a novel and innovative peptide technology platform through the collaboration with CNRS, gaining access to pioneering research centred on novel peptide drugs at the University of Bordeaux and the Institut Européen de Chimie et Biologie (IECB). The first therapeutic area being targeted is diabetes.

We are focused on advancing the care of patients suffering
from serious medical conditions worldwide.

Immupharma is AIM listed with our headquarters in London and research centres in France and Switzerland.

To contact us click here